SelectHealth will cover PGx testing for Intermountain employees and beneficiaries with major depressive disorder who have failed treatment.
A preliminary analysis lends some support to covering NIPS for pregnancies beyond high-risk, and some payors have expanded coverage.
NPR reports a large health insurer has begun to cover some pharmacogenetic tests for psychiatric drugs.
When used together, ThyGeNext and ThyraMir combine next-generation sequencing of an individual's DNA and RNA along with a microRNA classifier.
The study said that Cologuard was an "inefficient screening option" for colorectal cancer given its cost as compared to other CRC screening methods.
In response to CMS reopening its national coverage determination to address its germline testing policy, stakeholders point out areas of concern and confusion.
The Centers for Medicare & Medicaid Services announced it would cover approved CAR-T therapies for Medicare patients, according to the Associated Press.
The firm said that UHC will cover the test for patients with major depressive disorder or anxiety who have failed to respond to one or more treatments.
Blue Cross Blue Shield of Michigan's members will able to access Interpace's tests on an in-network basis, which will limit their out-of-pocket expenses.
Blue Shield of California's members will be able to access Interpace's tests on an in-network basis, which will limit their out-of-pocket expenses.
Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.
Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.
Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.
In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.